CD276 and cancer: Our analysis indicated a positive correlation between B3GNT5 and immune activation markers, including CD276, PVR, NT5E, STING1, and TNF-SF18 (Fig 9A), as well as immunosuppressive genes TGF-ΒR1, IL-10PR, KDR, CD274, PDCD1LG2, IL-10, and IDO1 in the pan-cancer cohort (Fig 7D).